Analysts Set Kenvue Inc. (NYSE:KVUE) PT at $23.08

Kenvue Inc. (NYSE:KVUE - Get Free Report) has earned a consensus rating of "Hold" from the twelve analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $23.08.

KVUE has been the topic of several research analyst reports. JPMorgan Chase & Co. boosted their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. UBS Group lowered their target price on shares of Kenvue from $24.00 to $23.00 and set a "neutral" rating on the stock in a research report on Thursday. Barclays reduced their price target on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research report on Friday. Citigroup dropped their price objective on Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research note on Wednesday. Finally, Bank of America boosted their target price on Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a research report on Tuesday, October 22nd.

Kenvue Stock Performance

Shares of Kenvue stock traded down $0.09 on Friday, reaching $21.11. 11,266,973 shares of the stock were exchanged, compared to its average volume of 8,612,558. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $40.46 billion, a PE ratio of 38.37, a PEG ratio of 1.99 and a beta of 1.46. Kenvue has a 1-year low of $17.67 and a 1-year high of $24.46. The business has a fifty day moving average price of $22.42 and a two-hundred day moving average price of $21.71.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. During the same period in the prior year, the business posted $0.31 EPS. The company's revenue for the quarter was down .4% on a year-over-year basis. As a group, research analysts anticipate that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.89%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue's dividend payout ratio is presently 149.09%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in KVUE. Grove Bank & Trust lifted its holdings in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after acquiring an additional 947 shares during the period. Riverview Trust Co purchased a new position in Kenvue during the third quarter worth approximately $30,000. Fortitude Family Office LLC raised its stake in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after purchasing an additional 777 shares during the period. Ashton Thomas Securities LLC acquired a new position in shares of Kenvue in the 3rd quarter valued at $35,000. Finally, Versant Capital Management Inc grew its stake in shares of Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after buying an additional 1,441 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.